tradingkey.logo

Zoetis Inc

ZTS
查看詳細走勢圖
121.720USD
-0.210-0.17%
收盤 01/29, 16:00美東報價延遲15分鐘
53.74B總市值
20.49本益比TTM

Zoetis Inc

121.720
-0.210-0.17%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.17%

5天

-2.15%

1月

-3.38%

6月

-19.40%

今年開始到現在

-3.26%

1年

-28.49%

查看詳細走勢圖

TradingKey Zoetis Inc股票評分

單位: USD 更新時間: 2026-01-29

操作建議

Zoetis Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名46/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為156.63。中期看,股價處於下降通道。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Zoetis Inc評分

相關信息

行業排名
46 / 159
全市場排名
128 / 4540
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Zoetis Inc亮點

亮點風險
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
利潤高增長
公司淨利潤處於行業前列,最新年度總收入9.26B美元
高分紅
公司屬於高分紅公司,最新股息支付率32.66%
穩定分紅
公司5年內持續分紅,最新股息支付率32.66%
估值低估
公司最新PE估值20.49,處於3年歷史低位
Mairs and Power 公司持倉
明星投資者Mairs and Power 公司持倉,最新持倉7.22K股

分析師目標

基於 20 分析師
買入
評級
156.628
目標均價
+25.34%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Zoetis Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Zoetis Inc簡介

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
公司代碼ZTS
公司Zoetis Inc
CEOPeck (Kristin C)
網址https://www.zoetis.com/
KeyAI